Overview

Novartis Everolimus Transition

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Transition from tacrolimus based triple therapy with Mycophenolate Mofetil (MMF) and steroids in stable renal transplant patients to low intensity tacrolimus, everolimus and prednisone will be associated with improvement in Glomular Filtration Rate (GFR) and allograft fibrosis.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
Novartis
Treatments:
Everolimus
Mycophenolate mofetil
Sirolimus
Tacrolimus